PALACE: Cemiplimab Trial According to ctDNA Levels
Status:
NOT_YET_RECRUITING
Trial end date:
2031-12-30
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.